HomeTagsBiotech

Biotech - Page 2

Stories from Biotech come first, newest first, then stories from connected topics (drug discovery, protein design, AI Science & Health, AI for science, Hub: Tech for Good, biology), each labelled with where it comes from. This view is not indexed by search engines.

Latest

Anthropic Says Claude Designed Binders Against Scorpion Neurotoxins

Anthropic says Claude designed protein binders against scorpion neurotoxins, with 17 of 211 tested designs meeting its criteria. It claims no antivenom.

Lilly Taps Metis TechBio’s AI to Steer Medicines to Target Tissues

Metis TechBio will use AI to design tissue-targeted drug carriers for Eli Lilly. Upfront cash is low double-digit millions; milestones run up to $1.1bn.

Scripps Research Gets Over 14 Million GPU Hours From Huang Foundation

Scripps Research gets more than 14 million GPU hours from the Huang Foundation via CoreWeave/NVIDIA. In-kind; no dollar value.

Johns Hopkins-Led Team Wins Up to $52.1m to Model Protein Misfolding

Johns Hopkins leads an ARPA-H award of up to $52.1m over four years for an open protein-misfolding AI model, starting with Parkinson’s and Ewing sarcoma.

China Proposes Adding 40 AI, Biomedicine and Solar Technologies to Its Export-Control Catalogue

China's commerce and science ministries propose adding 40 AI, biomedicine and solar technologies to the export-control catalogue, with registration now.

Sanofi Options First Development Candidate From Its Recursion AI Collaboration

Sanofi has optioned a potential first-in-class oral immunology candidate from Recursion, triggering a $10m milestone. Phase 1 is planned for 2027.

insitro and AstraZeneca Sign AI Collaboration to Hunt Drugs for MASH and Cardiomyopathies

insitro gets $40m upfront and is eligible for up to about $1.46bn in potential milestones in an AstraZeneca AI deal for MASH and heart disease.

Deep Origin and BioAge Labs Team Up on AI Drug Discovery, With First Hits Confirmed in the Lab

Deep Origin says its AI found drug hits against a new BioAge Labs target that BioAge has confirmed in the lab, in a new multi-target collaboration.

Baker Lab Uses AI to Design Enzymes That Cut Specific Proteins

Two Nature papers from David Baker's lab describe AI-designed enzymes that cut chosen proteins, including ones linked to disease. They are not treatments.

Generate Biomedicines and Zealand Pharma Team Up to Design Obesity Protein Drugs With AI

Zealand Pharma will pay Generate Biomedicines $30M upfront to design AI-engineered protein drugs for obesity, with milestones worth nearly $1.2 billion.

Latest on TSN

Explore the TSN Atlas: Every topic we cover, mapped. Click a bubble to dive in.